AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease

Journal of Neuroscience

Volumn 32, Issue 41, 2012, Pages 14311-14317

  Ng, Chee Hoe ^a   Guan, Melissa S H ^a   Koh, Cherlyn ^a   Ouyang, Xuezhi ^b   Yu, Fengwei ^b   Tan, Eng King ^a   O'Neill, Sharon Philomena ^c   Zhang, Xiaodong ^c,e,f   Chung, Jongkyeong ^d   Lim, Kah Leong ^a,c,e  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b TEMASEK LIFE SCIENCES LABORATORY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEUCINE RICH REPEAT KINASE 2; PARKIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLIMBING; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC ACTIVITY; DROSOPHILA; FEMALE; GENE MUTATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DOPAMINE; DROSOPHILA; FEMALE; HUMANS; MITOCHONDRIA; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RANDOM ALLOCATION;

EID: 84867269951     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0499-12.2012     Document Type: Article

References (30)

1. Chao J, Lau WK, Huie MJ, Ho YS, Yu MS, Lai CS, Wang M, Yuen WH, Lam WH, Chan TH, Chang RC (2010) A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine. Neurosci Lett 469:360-364. Crossref Medline
2. Choi JS, Park C, Jeong JW (2010) AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun 391: 147-151. Crossref Medline
3. Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 91:1161-1218. Crossref Medline
4. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909. Crossref Medline
5. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66:646-661. Crossref Medline
6. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM, Fitzpatrick J, Dillin A, Viollet B, Kundu M, Hansen M, Shaw RJ (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331:456-461. Crossref Medline
7. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 100: 4078-4083. Crossref Medline
8. Hardie DG (2011) AMP-activated protein kinase: anenergy sensor that regulates all aspects of cell function. Genes Dev 25:1895-1908. Crossref Medline
9. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetain CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neu-rol 7:583-590. Crossref Medline
10. Hwang JT, Kwon DY, Yoon SH (2009) AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphe-nols. N Biotechnol 26:17-22. Crossref Medline
11. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopami-nergic neurons in Drosophila. EMBO J 27:2432-2443. Crossref Medline
12. Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13:132-141. Crossref Medline
13. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, Wolozin B, Cookson MR (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 5:e8730. Crossref Medline
14. Kumari U, Tan EK (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276:6455-6463. Crossref Medline
15. Lee JH, Koh H, Kim M, Kim Y, Lee SY, Karess RE, Lee SH, Shong M, Kim JM, Kim J, Chung J (2007a) Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 447:1017-1020. Crossref Medline
16. Lee SB, Kim W, Lee S, Chung J (2007b) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358:534-539. Crossref Medline
17. Lim KL, Ng CH (2009) Genetic models of Parkinson disease. Biochim Bio-phys Acta 1792:604-615. Crossref Medline
18. Lim KL, Ng XH, Grace LG, Yao TP (2012) Mitochondrial dynamics and Parkinson's disease: focus on parkin. Antioxid Redox Signal 16:935-949. Crossref Medline
19. Mortiboys H, Johansen KK, Aasly JO, Bandmann O (2010) Mitochondrial impairmentinpatients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017-2020. Crossref Medline
20. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selec-tivelytoimpaired mitochondria and promotes their autophagy.J Cell Biol 183:795-803. Crossref Medline
21. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, Lim KL (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neu-rosci 29:11257-11262. Crossref Medline
22. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441:1157-1161. Crossref Medline
23. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis el-egans. J Neurosci 29:9210-9218. Crossref Medline
24. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269. Medline
25. Shults CW, Haas RH, Passov D, Beal MF (1997) Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinso-nian and nonparkinsonian subjects. Ann Neurol 42:261-264. Crossref Medline
26. Spasić MR, Callaerts P, Norga KK (2009) AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist 15:309-316. Crossref Medline
27. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN (2012) Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 18:753-758. Crossref Medline
28. Wang C, Lu R, Ouyang X, Ho MW, Chia W, Yu F, Lim KL (2007) Dro-sophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J Neurosci 27:8563-8570. Crossref Medline
29. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL (2011) PINK1 and Parkin target Miro for phos-phorylation and degradation to arrest mitochondrial motility. Cell 147: 893-906. Crossref Medline
30. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ (2005) Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A 102:8024-8029. Crossref Medline